



Universiteit
Leiden
The Netherlands

Outcome measures in Duchenne muscular dystrophy

Naarding, K.J.

Citation

Naarding, K. J. (2023, March 16). *Outcome measures in Duchenne muscular dystrophy*. Retrieved from <https://hdl.handle.net/1887/3571791>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3571791>

Note: To cite this publication please use the final published version (if applicable).

Chapter 1

General introduction

Duchenne muscular dystrophy

Clinical course

Duchenne muscular dystrophy (DMD) is a fatal and rare muscle wasting disease with an incidence of approximately 1 in 5000 new-born boys.^{1,2} The most frequently reported symptoms before diagnosis are gross motor delay, muscle weakness, difficulty walking, running and stair climbing, and frequent falls, whereas a proportion of patients show delay in cognitive and language development.³ Most boys without a family history are diagnosed before five years of age.⁴ Children with DMD suffer from a proximal to distal gradient of muscle weakness. The ambulatory phase of the disease can be divided into four clinical stages: early ambulatory, late ambulatory, early non-ambulatory and late-non-ambulatory.⁴ Clinical signs in the early ambulatory stage that can be observed are: delays in achieving developmental milestones, difficulties with running and jumping, a Gowers' sign, frequent falls and keeping up with peers regarding gross motor functions. The late ambulatory stage is characterized by a significantly reduced walking speed, fatigue and pain after walking long distances, the increased use of a wheelchair, and difficulties with rising from floor and stair climbing. Loss of independent ambulation defines the transition to the early non-ambulatory stage. Median age at loss of independent ambulation shifted from ten to 13 years of age due to the use of glucocorticoids, although the age range remains wide.^{5,6} Transition to late non-ambulatory stage is less clearly defined. Patients in the late non-ambulatory stage progressively require assistive devices to function independently, such as remote control units to operate electronic devices including televisions, computers and lights. For upper extremity function, arm muscle strength already decreases in the ambulant phase.⁷ In the early non-ambulatory stage patients increasingly experience difficulties raising the arms due to loss of shoulder strength. Upper arm function, such as the ability to move the hand to the mouth, is preserved until the mid-teens.⁵ In the late non-ambulatory phase patients have limited arm and hand function left. Hand function is preserved into the twenties, although hand strength of DMD patients has been found to be lower than that of healthy peers as early as five years of age.^{5,8} Preservation of minimum function of hand muscles can significantly improve participation in daily life for patients in this stage, because it could allow them to use electronic devices such as an electric wheelchair, smartphone, tablet, computer or a game console.⁹

Not only motor functioning is affected by the absence of dystrophin, but clinical manifestations can also be observed in for instance the heart and the brain. Examples of the cognitive manifestations are a higher prevalence of learning and behavioral disabilities in DMD compared to the general population.¹⁰

Pathophysiology

DMD is an X-linked inherited neuromuscular disorder caused by mutations in the *DMD* gene located at the short arm of the X chromosome (Xp21 locus). The *DMD* gene consists of 79 exons that together encode the dystrophin protein. The mutations causing DMD lead to

premature termination of dystrophin production and thereby nearly complete absence of the full-length dystrophin protein.¹¹

Becker muscular dystrophy (BMD) is also caused by mutations in the *DMD* gene, but in general these mutations do not lead to absence of dystrophin, but to a partly functional dystrophin protein with an altered molecular weight. BMD patients have a more variable and generally milder disease course.^{12, 13}

The full-length dystrophin protein is expressed in skeletal muscle, where it stabilizes the muscle fiber membrane and protects it from contraction induced damage.¹⁴ It also has a function as signaling complex in skeletal muscle by providing binding sites for signaling proteins such as nitric oxide synthase.¹⁴ In DMD, disruption of these functions is assumed to cause muscle fibers to be easily damaged, which leads to fiber degeneration and regeneration, inflammation and finally muscle wasting with irreversible replacement of muscle fibers with fat and fibrotic tissue (Figure 1).¹⁵




Figure 1. Biopsy of dystrophic muscle

Muscle biopsy of an anonymous healthy control (left) and DMD patient (right) from the Leiden University Medical Center. The dystrophic biopsy shows variation in size and shape of the muscle fibers with regeneration, some necrosis, inflammation, fibrosis and fatty replacement. *Kindly provided by Dr. S.G. van Duinen.*

Dystrophin proteins with different lengths (i.e. isoforms) are encoded by the *DMD* gene. The full-length dystrophin protein is the primary isoform in skeletal muscle, but at least three dystrophin isoforms are also expressed in the brain: full-length Dp427, and the shorter Dp140 and Dp71 (Figure 2).¹⁶ The location of the mutation within the *DMD* gene influences the number of dystrophin isoforms that are lacking. In Figure 2, a mutation at location A (exon 1 until 44) will only lead to absence of Dp427. In case of a mutation at location B (exon 51 until 62), Dp140 will be lacking in addition to Dp427. Finally, a mutation at location C (exon 63 until 79) will lead to absence of all three dystrophin isoforms. DMD patients lacking the Dp140 isoform have been demonstrated to on average perform more poorly on neuropsychological tests and have a higher incidence of learning and behavioral disabilities.^{17,}

¹⁸ These seem even more pronounced in patients lacking all three brain isoforms.^{19, 20}




Figure 2. Mutation locations of dystrophin isoforms

Image representing mutation locations in the *DMD* gene and their effect on the different dystrophin isoform expression. The full-length dystrophin Dp427 and the shorter Dp140 and Dp71 isoforms are present in the healthy brain. A mutation at location A, in exon 1 until 44, will only lead to absence of Dp427. Dp140 will be lacking in addition to Dp427 with a mutation at location B, in exon 51 until 62. A mutation at location C, which is in exon 63 until 79, will lead to absence of all three dystrophin isoforms. *Modified with permission from Dr. N. Doorenweerd.*

Clinical trials in DMD and the importance of outcome measures

The International standards of care for DMD have been published in 2010 and updated in 2018. Guidelines on the implementation of these standards of care in the Dutch healthcare system can be found on the website of the Duchenne Center Netherlands: www.duchenneexpertisecentrum.nl/passende-zorg/zorgverleners/duchenne-richtlijn/.^{4, 21, 22} Treatment with glucocorticoids is recommended and has been shown to delay loss of ambulation and upper limb disease progression, to reduce the need for scoliosis surgery, to improve pulmonary function, and to delay cardiomyopathy onset.^{5, 23} Life expectancy has shifted to the late twenties and thirties due to the combination of improved cardiac care, orthopedic interventions, the use of glucocorticoids and, most importantly, advancements in respiratory care such as air stacking, use of cough assist devices, and assisted ventilation.^{24, 25} Nonetheless, more severely affected patients can still die in the late teens or early twenties. A fully approved cure for DMD is currently lacking, but three dystrophin-restoring drugs have received conditional approval, two by the U.S. Food and Drug Administration (FDA) and another one by the European Medicines Agency (EMA).^{26, 27} Unfortunately, these drugs only seem to have a limited effect on disease progression.²⁶

Over the past decade, many clinical trials in DMD have been conducted in primarily ambulant patients to study effectiveness of therapies aiming at dystrophin restoration or improvement of muscle quality, and many trials are still being conducted.²⁶ Assessment of the safety and efficacy of a new therapy follows a standardized order. After preclinical studies, a new drug is studied in humans in four sequential clinical trial phases. In phase I, the optimal dosage is determined based on safety in healthy volunteers. In phase II, efficacy and side effects are assessed in a small group of patients. In DMD, phase I and II are often combined and

called phase II, because of potential harm in healthy volunteers when RNA modifying drugs are used, such as antisense oligonucleotides designed to alter RNA splicing. Phase II is sometimes split in IIa and IIb, where phase IIa is specifically designed to assess the required dose and phase IIb to study efficacy in a small group of patients. Phase III is used to assess efficacy, effectiveness and safety in a larger patient population, that is predefined using a power calculation based on the effect in the phase II trials, compared to a placebo. In such randomized controlled trials (RCT), patients are randomized into the study drug arm or comparative arm, and both patients and study personnel, including clinicians and clinical evaluators, are blinded for the received treatment. It is the last phase before approval is requested from the regulators. Phase IV consists of post-marketing surveillance.

Phase III trials have a number of important characteristics. The main purpose is to demonstrate the effect of the intervention on one outcome measure, the primary endpoint. Secondary endpoints may contribute supportive information about the effectiveness of a drug, but they are less important for drug approval, because the sample size was usually not determined to find an effect on secondary endpoints. Approval of the regulatory agencies to use an outcome measure as primary endpoint depends on the natural history of the disease, the disease phase that is studied, the availability of outcome measures, and the expected effect and mechanism of action of the intervention.²⁸

When the first phase IIb RCT in DMD was conducted using ataluren as stop codon readthrough in 2008, the six minute walking test (6MWT) was available from pulmonary and metabolic disease studies and was acceptable for regulators as primary endpoint in DMD.²⁹⁻

³¹ However, no natural history data were available at that time, and it was not until the placebo arm of this trial was analyzed that it became clear that the total distance walked in the 6MWT by DMD patients first improved with age due to maturation, then stabilized and finally declined due to disease progression until loss of ambulation (Figure 3).³² Many natural history studies have since described that 6MWT distances vary largely between and within patients over time due to the non-linear progression, different progression rates, and other factors such as interobserver variation and motivational issues (Figure 3).³²⁻³⁵ The ataluren RCT demonstrated the hurdles that arise in a maturing population of ambulant DMD patients with a heterogeneous disease course, an outcome measure that has a motivational component and with drugs that potentially limit the progression rather than improve muscle strength, and thus have a limited effect. This initiated research into the natural history and the development of new outcome measures.²⁸ As a consequence, following trials narrowed inclusion criteria to select a more homogenous study population, which complicated study inclusion in this rare disease. Furthermore, different primary endpoints were selected that potentially had a linear progression and were more sensitive to change, such as the North Star Ambulatory Assessment (NSAA), the time to climb four stairs and the time to rise from the floor (examples of trials using these as primary endpoint: NCT04281485, NCT04632940, NCT02851797, NCT04587908 and NCT03439670).^{28, 36, 37} The NSAA is an assessment of ambulatory motor performance that consists of 17 items and yields a maximum score of 34 points.³⁷




Figure 3. Six minute walking test (6MWT) change over time data

Variability in 6MWT distance results of DMD patients from the Leiden University Medical Center outpatient clinic cohort. Age at loss of ambulation is plotted as 0 meters.

In the past, the FDA and EMA have ruled differently in the conditional approval phase of new treatments for DMD. The FDA ruled in favor of treatments that demonstrated an increase of dystrophin levels, which has a causal relation with the symptoms in DMD and therefore were anticipated to have a potential clinical benefit upon continued treatment.³⁸ The FDA conditionally approved eteplirsen based on an open label study that showed a minor increase in dystrophin levels of up to 0.9% after 180 weeks of treatment.^{26, 39} The EMA ruled in favor of treatments that demonstrated a clinically relevant effect for patients, and expected this to originate from the intended effect of a therapy.⁴⁰ The EMA therefore conditionally approved ataluren based on a subgroup analysis that showed a 6MWT difference of 68.2 meters and a favorable side-effect profile, although the study did not meet the primary endpoint for the whole group.^{26, 29} These differences in the FDA's and EMA's rulings thus led to conditional approval of one drug by the FDA that the EMA did not approve, and vice versa.²⁶

There are several types of outcome measures: clinical outcome measures that require specific patient related tasks, such as the 6MWT or Performance of the Upper Limb, patient reported outcome measures, such as the DMD Upper Limb Patient Reported Outcome Measure (PROM), and biomarkers that for example reflect tissue characteristics, such as fat fraction measured using muscle magnetic resonance imaging (MRI), or dystrophin levels using muscle biopsies, or circulating muscle related micro RNA or proteins in blood or urine samples. Clinical relevance could be assumed for clinical outcome measures and patient

reported outcome measures that are relevant for a specific disease and disease stage, although the amount of change that is clinically relevant is topic of debate. For biomarkers clinical relevance is less clear. One method to study clinical relevance is by using the biomarker to predict loss of an important disease milestone, such as the ability to ambulate or to bring a glass to the mouth. Another method is to determine the minimally clinically important difference, for instance via the Delphi method by using a panel of experts, or via an anchor-based approach where the biomarker is linked to an independent measure with clinical relevance to patients, such as a global rating of change.^{41, 42}

All outcome measures should demonstrate sufficient reliability, construct validity, concurrent validity, longitudinal change and accessibility. A measure is reliable, when repeated tests lead to similar results. Construct validity is the extent to which the test measures what it is intended to measure. Concurrent validity is the extent to which the studied outcome measure correlates with an established outcome measure. An outcome measures should be sensitive to longitudinal change in DMD, even more so because therapies so far have been expected to reach a stabilizing effect in this progressive disease. The sensitiveness to change of the outcome measure and the expected effect of a therapy together determine the number of participants that is required per clinical trial. Due to its variability between patients and within patients over time, the 6MWT required relatively large sample sizes.^{33, 34} A more sensitive outcome measure or more effective drugs would obviously lead to a smaller required sample size and thus increase the likelihood of such a trial to be completed successfully.⁴³ Accessibility of outcome measures is important in DMD, because trials are usually conducted worldwide over a period of years due to the rarity of the disease and use of stringent in- and exclusion criteria. Outcome measures should therefore preferably be easily operatable and accessible to use over a long period of time. It can be considered to improve existing outcome measures by changing the included items, however, the disadvantage is that new natural history data is required, such as with the improvement of the Performance of the Upper Limb from version 1.2 to 2.0.^{44, 45}

Another important characteristic of phase III trials are the in- and exclusion criteria, which influence the generalizability of the results. Inclusion criteria often contain a statement that patients have to be able to follow study instructions, which could be harder for patients with learning and behavioral disabilities. This could result in inclusion of less patients with a distal mutation in exon 63-79, because of a higher prevalence of these symptoms in this population. Whether specific patient characteristics influence the likeliness to participate in studies could be studied by comparing baseline characteristics of participating patients to patients who were eligible but decided together with their parents to refrain from participation.

Outcome measures of the upper extremities

Outcome measures of lower extremity function, such as the 6MWT, can only be used in ambulant patients. Drugs that restore dystrophin or improve the muscle quality need sufficient muscle tissue to target and the progressive replacement of muscle by fat and fibrosis, currently considered to be irreversible, limits the amount of muscle that can be targeted. Therefore, drugs that are proven effective in ambulant patients need to be studied separately and with different outcome measures in non-ambulant patients before the EMA and FDA will approve use in these populations as well.^{38, 40} Most studies in non-ambulant patients have focused on the early non-ambulant phase. The available outcome measures often have a floor and ceiling effect showing little to no longitudinal change in patients who have limited function left or have little functional impairment. An example is the stable phase in the 6MWT and a maximum PUL score in many ambulant patients.^{34, 46} In addition, there is a lack of outcome measures that are suitable for the more advanced stages of the disease. For known outcome measures there is a need for longitudinal natural history data in non-ambulant patients. Examples are strength tests, the Performance of the Upper Limb (PUL) motor function measure and the PROM. To overcome issues of the described outcome measures, innovative outcome measures and their characteristics could be explored, such as Kinect and Leap Motion outcome measures and quantitative muscle MRI.

Upper extremity muscle strength tests

Muscle strength is considered an important outcome measure, because it can quantitatively assess the clinical effect of the underlying muscle pathology in DMD.⁴⁰ However, it is not approved as primary endpoint, because FDA and EMA ruled that clinical relevance has to be established.⁴⁰ Muscle strength can be measured reliably using a hand-held dynamometer,⁴⁷ but this method cannot be used to assess distal muscle function in very weak patients. For this the MyoGrip and MyoPinch have been developed to assess isometric grip and pinch strength respectively (Figure 4).⁴⁸ The smallest change that can be measured is 0.01 kg for the MyoGrip and 0.001 kg for the MyoPinch. Both devices have been shown to be reliable and to show differences between DMD patients and controls.⁴⁸ Disadvantages are the need for a trained assessor, and vulnerable accessibility with a single manufacturer that is also needed for maintenance. Furthermore, the ability of MyoGrip and MyoPinch to predict important disease milestones has not yet been demonstrated.

Performance of the Upper Limb

The only approved outcome measure in non-ambulant patients is the Performance of the Upper Limb (PUL).^{44, 45} It has been used as primary endpoint in two recent clinical trials in non-ambulant patients (NCT03406780 and NCT04371666). The first widely used version of the PUL was version 1.2 consisting of 20 items with a maximum total score of 74 points. Using a Rasch analysis and input from clinicians, the scoring per item was simplified to options of 0, 1, or 2 points and some items were removed because of redundancy and some



Figure 4. MyoGrip and MyoPinch

MyoGrip (left) and MyoPinch (right) devices are shown with the correct positions during strength measurements.

were separated or added.⁴⁵ The resulting PUL 2.0 consists of 22 motor items that are assessed by an observer and it yields a maximum total score of 42 points.⁴⁵ The items can be divided into three dimensions with a maximum score of 12 for the shoulder dimension, 17 for the elbow dimension and 13 for the distal wrist/hand dimension. During the course of this thesis, the first PUL longitudinal natural history data in DMD has been published. For a cohort of 177 DMD patients the annual change was found to be -1.5 points, where non-ambulant patients lost on average 1.1 points more than ambulant patients.⁴⁹ Limitations of the PUL are a ceiling effect in the upper and lower regions of the score and observer-dependence. Its prediction of important disease milestones has not yet been demonstrated, nor is a minimal clinically important difference available.

Patient reported outcome measures for the upper extremity

For the upper extremity in DMD there is one patient reported outcome measure: the DMD Upper Limb Patient Reported Outcome Measure (PROM). The most recent version of the PROM questionnaire contains 32 daily-life activity items which are scored on a three-level scale ('cannot do'; 'with difficulty'; 'easy') with a maximum total score of 64 points.⁵⁰ It describes self-reported meaningful upper extremity daily-life activities that could not otherwise be observed in a clinical or research setting (e.g. feeding, washing, and leisure activities). Internal consistency and test-retest reliability have been demonstrated.⁵⁰ Advantages are the fact that an assessor is not required and that data can be acquired off-site. Disadvantages are the subjective nature of the questionnaire and the current lack of change over time data and a minimal clinically important difference, reflecting relevant change for a patient. The FDA and EMA recommend the use of Patient Reported Outcome Measures as secondary outcome measure, because these can aid in determining clinical meaningfulness of objective findings of small magnitude, contribute to the assessment of benefit and risk, and assess the effect of a therapy on daily life activities.^{38, 40}

Innovative outcome measures using Leap Motion and Microsoft Kinect

The Leap Motion controller and Microsoft Kinect v2 sensor are two innovative, low-cost marker-less motion capture systems that were developed by the gaming industry. Outcome measures of upper extremity motor function using these devices provide a continuous outcome parameter without a maximum score. This mitigates disadvantages of current outcome measures, such as a floor and ceiling effect. The Leap Motion controller uses infrared cameras to estimate the location of wrist and hand joints. This information can be used to calculate active ranges of motion (aROM) of these joints, and could have potential as outcome measure in advanced stages of DMD.⁵¹ The Kinect obtains depth data with an infrared laser transmitter and an infrared camera. Using this data, real-time 3D-coordinates of body points, including the head, shoulders, elbows and wrists, are provided to estimate human posture. So far, two methods have used Kinect to assess the reaching ability of the arms in DMD: the 'reachable workspace envelope relative surface area' (RSA) and the 'Ability Captured Through Interactive Video Evaluation' (ACTIVE).^{52,53} Both measures could be used to objectively quantify upper extremity motor function without ceiling effect or observer-dependence, and might therefore be more sensitive to disease progression. Potential drawbacks could be the lack of insight in constraints of the software and hardware due to intellectual property, and possible software updates and hardware discontinuation which could jeopardize their use in clinical trials.

Quantitative muscle MR methods

Quantitative muscle magnetic resonance (qMR) methods such as MRI and MR spectroscopy (MRS) can be used to assess muscle pathology in muscular dystrophies including DMD. qMR is considered to be a promising biomarker, because it has the potential to accurately assess different aspects of muscle wasting in this muscle wasting disease.⁵⁴⁻⁵⁹ MRI is non-invasive and safe, and most patients aged five years and older tolerate scanning up to one hour well without anesthesia.⁶⁰⁻⁶² However, lying still for prolonged periods of time in a specific position can be strenuous for patients. qMR methods of the lower extremity have been shown to accurately describe fat replacement and tissue edema in DMD, and to have excellent test-retest reproducibility within and across centers.^{55, 57-59, 63-66}

At the start of the projects described in this thesis, muscle MRI of the upper extremities had only been studied in small cohorts of primarily ambulant DMD patients and mainly of the forearm muscles.^{58, 67, 68} Muscle MRI of the upper extremities could pose extra hurdles compared to the lower extremities, because of the smaller muscle mass and position of the arms at the side of the body and therefore not in the center of the MR scanner, which decreases the image quality and frequently causes artefacts. A position where the participants are lying on their side could be chosen to overcome the off-center position of the upper extremity, but this could be difficult for patients to maintain.

Different qMR techniques can be used to measure fat replacement and tissue edema. Muscle fat fraction (FF) is the most studied qMR parameter and can be assessed using water-fat MRI scans or MRS. MRS is the gold standard for FF determination with a high accuracy and reproducibility.⁶⁵ A disadvantage of MRS is that results are usually obtained for one pre-specified region of interest, resulting in information for only a specific part of a single muscle or muscle group. Therefore, information about spatial variation within or between muscles cannot be obtained. Tissue edema or inflammation can be studied via the T2 relaxation time of water in the muscle ($T2_{\text{water}}$), which can be determined using multi-echo spin-echo (MSE) imaging or spectroscopy sequences.⁶⁹⁻⁷¹

Fat-water imaging

Chemical shift based fat-water imaging is based on the difference in precession speed between protons in water and fat.⁶⁵ In a technique originally shown by Dixon,⁷² images are acquired at different echo times, or phases, and from these images a purely water and fat image can be obtained (Figure 5). The FF in a specific area, typically a single muscle or muscle group, can be calculated by dividing the signal on the fat image by the combined signal of the water and fat image in that area.




Figure 5. Dixon muscle MRI images of the extremities

Dixon water and fat images of thigh, upper arm, and hand muscles of healthy controls and DMD patients. In the figure, arrows point at the following tissues: healthy muscle, muscle replaced by fat, subcutaneous fat, and bone.

qMR muscle fat fraction

In the lower extremities, muscle FF has been shown to increase with age and to correlate with motor function tests and strength of specific muscle groups.^{54, 57, 58, 73, 74} A study by Willcocks et al. illustrated that FF is more sensitive to disease progression than functional tests, by showing that FF increased significantly over 12 months, even in some boys in whom 6MWT distances increased due to growth.⁵⁸ Also in forearm muscles FF has been shown to increase over six or 12 months, and in upper arm muscles FF correlated with the PUL and grip and pinch strength.^{67, 68, 75} In non-ambulant patients, limited data on qMR FF of upper arm muscles is available.⁷⁵ No studies have examined very distal muscles in DMD, which are thought to be relatively spared in advanced disease stages.

Furthermore, the extensively described correlations between muscle FF, strength, and function at the time of qMR do not prove causality.^{54, 56, 57, 68, 74, 76-79} Even unrelated biological parameters that consistently increase or decrease with age will inherently correlate with functional parameters in a progressive disease. Therefore, such correlations alone are not sufficient to show clinical relevance of muscle FF. For this, qMR FF should be able to predict loss of an important disease milestone, such as the ability to ambulate or bring a glass to the mouth. Such a predictive ability has not yet been demonstrated, and would help to qualify muscle qMR FF as outcome measure that can be used as primary or secondary endpoint in trials.

T2 relaxation time of water in muscle

The T2 relaxation time is an MR parameter which is prolonged by increased water mobility, such as in inflammation, necrosis and fatty replacement.⁷⁰ The T2 relaxation time of water in muscle ($T_{2_{\text{water}}}$) is relatively short. This parameter has been used to study tissue edema or inflammation, and thus disease activity, as these changes are thought to occur in muscles prior to fat replacement and fibrosis.⁶⁹⁻⁷¹ $T_{2_{\text{water}}}$ can be determined accurately using MRS, as water and fat signals can be easily discriminated using this method. However, this method is commonly applied using a single voxel approach due to time constraints, and hence only data are acquired from a pre-specified region of interest.

$T_{2_{\text{water}}}$ can also be determined with an imaging based method using an MSE sequence. In this way, spatial information is preserved and data can be obtained for a large field of view that covers different muscles or muscle groups. The T2 relaxation time of fat ($T_{2_{\text{fat}}}$) is much longer (~ 130-170 ms at 3 Tesla) than the $T_{2_{\text{water}}}$ in muscle (25-30ms), and the increase in $T_{2_{\text{water}}}$ due to disease activity (~ 1-4 ms).⁶⁹⁻⁷¹ An MRI MSE sequence consist of multiple spin echoes from which the 'global' T2 relaxation time can be determined using a mono-exponential fit of the signal decay as a function of the echo time (Figure 6).⁷⁰ This global T2 consists of both the signal decay of water and fat. In DMD, due to progressive fat replacement, the signal of fat dominates the value of the global T2. Therefore, it is necessary to separate the signal decay into a water and fat component, to determine the $T_{2_{\text{water}}}$ and $T_{2_{\text{fat}}}$ (Figure 6).⁷¹




Figure 6. T2 relaxation time

MRI signal as a function of the echo time, where the signal of water and fat combined is shown with a dotted line which decays due to 'global' T2 relaxation. The water (blue line) signal experiences a different T2 relaxation ($T2_{\text{water}}$) than the fat (yellow) signal ($T2_{\text{fat}}$). This global T2 relaxation can be separated in the T2 relaxation time of fat (yellow) and water (blue). *Kindly provided by K.R. Keene.*

$T2_{\text{water}}$ has been studied as a qMR marker for disease activity,^{69,70} and in young DMD patients, lower extremity muscles with limited fat replacement were shown to have an elevated $T2_{\text{water}}$.⁶⁹ Some data on $T2_{\text{water}}$ in forearm muscles is available, but $T2_{\text{water}}$ is more difficult to interpret in fat replaced muscles and therefore more difficult to study in advanced disease stages.⁶⁸ No studies have examined $T2_{\text{water}}$ in very distal muscles, which might show interesting results in advanced disease stages in case of limited fat replacement.

Objectives of this thesis

DMD is a rare and fatal muscle wasting disorder. Beside chronic use of glucocorticoids there is currently no fully approved therapy available. Due to improved care and glucocorticoids, patients have a longer life-expectancy and therefore go longer through life in the non-ambulant phase. The importance of outcome measures and natural history data was demonstrated when the 6MWT was used as primary endpoint in the first clinical trials in DMD. Outcome measures should demonstrate sufficient reliability, construct validity, concurrent validity, longitudinal change and accessibility. Clinical relevance of outcome measures should also be demonstrated, for instance via their relation with important disease milestones. Due to a progressive reduction in muscle tissue to be targeted by drugs, separate clinical trials need to be performed in non-ambulant patients, therefore specific outcome measures are required for this disease stage.

The overall aim of this thesis was to identify outcome measures in DMD, specifically for non-ambulant patients, that detect an effect of a new therapy that is clinically relevant for

patients in a relatively short period of time according to what is feasible in clinical trials. The use of such outcome measures could lead to a reduction in the sample sizes and potentially to a lower burden for patients.

Outline of this thesis

Chapter 2 describes reasons why DMD and BMD patients and parents declined participation in observational studies and discusses the presence of selection bias by comparing characteristics of participants and non-participants in these studies. These results can be used to optimize patient participation in studies on this rare disease and to stimulate representative observational research.

Chapter 3 describes the relation between quantitative MRI (qMRI) FF of a lower extremity muscle and loss of ambulation on top of the effect of age in ambulant patients with DMD. The aim was to predict the loss of this important milestone and thus establish the clinical relevance of muscle qMRI FF to support its use as an outcome measure in clinical trials.

Chapter 4 describes the relation between qMRI FF of an upper extremity muscle and loss of hand-to-mouth movement on top of the effect of age in non-ambulant patients with DMD. The aim was to establish clinical relevance by predicting the loss of this important upper extremity disease milestone and thus to support the use of muscle qMRI FF in clinical trials in non-ambulant patients.

Chapter 5 describes qMRI results of the thenar muscles and hand function over one year to establish the value of the thenar muscles for monitoring treatment effects in non-ambulant DMD patients. Preservation of these muscles and measurable disease progression in these muscles would indicate that the thenar muscles are a valuable and quantifiable biomarker and target for systemic or local therapy in the later non-ambulant stages of the disease.

Chapter 6 illustrates the potential and constraints of using sensors from the gaming industry to develop upper extremity outcome measures for non-ambulant patients with DMD. The results of these novel outcome measures are compared to the currently used PUL and PROM outcome measures.

References

1. Mendell JR, Shilling C, Leslie ND, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. *Ann Neurol* 2012;71:304-313. doi:10.1002/ana.23528
2. Moat SJ, Bradley DM, Salmon R, et al. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). *Eur J Hum Genet* 2013;21:1049-1053. doi:10.1038/ejhg.2012.301
3. Ciafaloni E, Fox DJ, Pandya S, et al. Delayed Diagnosis in Duchenne Muscular Dystrophy: Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). *J Pediatr-Ur* 2009;155:380-385. doi:10.1016/j.jpeds.2009.02.007
4. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet Neurol* 2018;17:251-267. doi:10.1016/S1474-4422(18)30024-3
5. McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. *Lancet* 2018;391:451-461. doi:10.1016/S0140-6736(17)32160-8
6. van den Bergen JC, Ginjaar HB, van Essen AJ, et al. Forty-Five Years of Duchenne Muscular Dystrophy in The Netherlands. *J Neuromuscul Dis* 2014;1:99-109
7. Janssen M, Harlaar J, Koopman B, de Groot IJM. Dynamic arm study: quantitative description of upper extremity function and activity of boys and men with duchenne muscular dystrophy. *J Neuroeng Rehabil* 2017;14:45. doi:10.1186/s12984-017-0259-5
8. Hogrel JY, Decostre V, Ledoux I, et al. Normalized grip strength is a sensitive outcome measure through all stages of Duchenne muscular dystrophy. *Journal of neurology* 2020;267:2022-2028. doi:10.1007/s00415-020-09800-9
9. Heutinck L, Kampen NV, Jansen M, Groot IJ. Physical Activity in Boys With Duchenne Muscular Dystrophy Is Lower and Less Demanding Compared to Healthy Boys. *J Child Neurol* 2017;32:450-457. doi:10.1177/0883073816685506
10. Banihani R, Smile S, Yoon G, et al. Cognitive and Neurobehavioral Profile in Boys With Duchenne Muscular Dystrophy. *J Child Neurol* 2015;30:1472-1482. doi:10.1177/0883073815570154
11. Monaco AP, Bertelson CJ, Liechti-Gallati S, et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. *Genomics* 1988;2:90-95
12. Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. *Journal of neurology* 1993;240:98-104. doi:10.1007/BF00858725
13. Clemens PR, Niizawa G, Feng J, et al. The CINRG Becker Natural History Study: Baseline characteristics. *Muscle Nerve* 2020;62:369-376. doi:10.1002/mus.27011
14. Allen DG, Whitehead NP, Froehner SC. Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca²⁺, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy. *Physiol Rev* 2016;96:253-305. doi:10.1152/physrev.00007.2015
15. Cros D, Harnden P, Pellissier JF, Serratrice G. Muscle hypertrophy in Duchenne muscular dystrophy. A pathological and morphometric study. *Journal of neurology* 1989;236:43-47. doi:10.1007/bf00314217
16. Doorenweerd N, Mahfouz A, van Putten M, et al. Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy. *Sci Rep* 2017;7:12575. doi:10.1038/s41598-017-12981-5
17. Chamova T, Guergueltcheva V, Raycheva M, et al. ASSOCIATION BETWEEN LOSS OF Dp140 AND COGNITIVE IMPAIRMENT IN DUCHENNE AND BECKER DYSTROPHIES. *Balk J Med Genet* 2013;16:21-29. doi:10.2478/bjmg-2013-0014
18. Ricotti V, Mandy WPL, Scoto M, et al. Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations. *Developmental Medicine and Child Neurology* 2016;58:77-84. doi:10.1111/dmcn.12922
19. Taylor PJ, Betts GA, Maroulis S, et al. Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy. *PLoS One* 2010;5:e8803. doi:10.1371/journal.pone.0008803
20. Pane M, Lombardo ME, Alfieri P, et al. Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation. *J Pediatr* 2012;161:705-709 e701. doi:10.1016/j.jpeds.2012.03.020
21. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. *Lancet Neurol* 2018;17:347-361. doi:10.1016/S1474-4422(18)30025-5
22. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. *Lancet Neurol* 2018;17:445-455. doi:10.1016/S1474-4422(18)30026-7

23. Gloss D, Moxley RT, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology* 2016;86:465-472. doi:10.1212/WNL.0000000000002337
24. Landfeldt E, Thompson R, Sejersen T, et al. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. *Eur J Epidemiol* 2020;35:643-653. doi:10.1007/s10654-020-00613-8
25. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurol* 2010;9:77-93. doi:10.1016/S1474-4422(09)70271-6
26. Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. *Nature reviews Neurology* 2019;15:373-386. doi:10.1038/s41582-019-0203-3
27. Roy B, Griggs R. Advances in Treatments in Muscular Dystrophies and Motor Neuron Disorders. *Neurol Clin* 2021;39:87-112. doi:10.1016/j.ncl.2020.09.005
28. Straub V, Mercuri E, Grp DOMS. Report on the workshop: Meaningful outcome measures for Duchenne muscular dystrophy, London, UK, 30-31 January 2017. *Neuromuscular Disorders* 2018;28:690-701. doi:10.1016/j.nmd.2018.05.013
29. Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. *Muscle Nerve* 2014;50:477-487. doi:10.1002/mus.24332
30. Mendell JR, Goemans N, Lowes LP, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. *Ann Neurol* 2016;79:257-271. doi:10.1002/ana.24555
31. McDonald CM, Henricson EK, Han JJ, et al. The 6-Minute Walk Test as a New Outcome Measure in Duchenne Muscular Dystrophy. *Muscle & Nerve* 2010;41:500-510. doi:10.1002/mus.21544
32. McDonald CM, Henricson EK, Abresch RT, et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. *Muscle Nerve* 2013;48:343-356. doi:10.1002/mus.23902
33. Goemans N, Vanden Hauwe M, Signorovitch J, et al. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy. *PLoS One* 2016;11:e0164684. doi:10.1371/journal.pone.0164684
34. Mercuri E, Signorovitch JE, Swallow E, et al. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. *Neuromuscul Disord* 2016;26:576-583. doi:10.1016/j.nmd.2016.05.016
35. Arora H, Willcocks RJ, Lott DJ, et al. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history. *Muscle & Nerve* 2018;58:631-638. doi:10.1002/mus.26161
36. McDonald CM, Henricson EK, Abresch RT, et al. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. *Muscle Nerve* 2013;48:357-368. doi:10.1002/mus.23905
37. Mazzone E, Martinelli D, Berardinelli A, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. *Neuromuscul Disord* 2010;20:712-716. doi:10.1016/j.nmd.2010.06.014
38. CDER, CBER. Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment. Guidance for Industry. <https://www.fda.gov/media/92233/download>. Accessed on May 1, 2019. US Food & Drug Administration (FDA) 2018
39. Charleston JS, Schnell FJ, Dworzak J, et al. Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production. *Neurology* 2018;90:e2146-e2154. doi:10.1212/WNL.0000000000005680
40. CHMP. Guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy. In European Medicines Agency (EMA). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/12/WC500199239.pdf. Accessed December 18, 2020.
41. Johnston BC, Ebrahim S, Carrasco-Labra A, et al. Minimally important difference estimates and methods: a protocol. *Bmj Open* 2015;5. doi:ARTN e007953
- 10.1136/bmjopen-2015-007953
42. King MT. A point of minimal important difference (MID): a critique of terminology and methods. *Expert Rev Pharm Out* 2011;11:171-184. doi:10.1586/Erp.11.9
43. Straub V, Balabanov P, Bushby K, et al. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. *Lancet Neurol* 2016;15:882-890. doi:10.1016/S1474-4422(16)30035-7
44. Mayhew A, Mazzone ES, Eagle M, et al. Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy. *Dev Med Child Neurol* 2013;55:1038-1045. doi:10.1111/dmcn.12213
45. Mayhew AG, Coratti G, Mazzone ES, et al. Performance of Upper Limb module for Duchenne muscular dystrophy. *Dev Med Child Neurol* 2019. doi:10.1111/dmcn.14361

46. Pane M., Mazzone E.S., Sivo S., et al. The 6 minute walk test and performance of upper limb in ambulant duchenne muscular dystrophy boys. *PLoS Curr* 2014. doi:10.1371/currents.md.a93d9904d57dcb08936f2ea89bca6fe6
47. Mendell JR, Florence J. Manual muscle testing. *Muscle Nerve* 1990;13 Suppl:S16-20. doi:10.1002/mus.880131307
48. Servais L, Deconinck N, Moraux A, et al. Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients. *Neuromuscul Disord* 2013;23:139-148. doi:10.1016/j.nmd.2012.10.022
49. Pane M, Coratti G, Brogna C, et al. Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. *PLoS One* 2018;13:e0199223. doi:10.1371/journal.pone.0199223
50. Klingels K, Mayhew AG, Mazzone ES, et al. Development of a patient-reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM. *Dev Med Child Neurol* 2017;59:224-231. doi:10.1111/dmcn.13277
51. Nizamis K, Rijken NHM, Mendes A, et al. A Novel Setup and Protocol to Measure the Range of Motion of the Wrist and the Hand. *Sensors (Basel)* 2018;18. doi:10.3390/s18103230
52. Han JJ, de Bie E, Nicorici A, et al. Reachable workspace and performance of upper limb (PUL) in duchenne muscular dystrophy. *Muscle Nerve* 2016;53:545-554. doi:10.1002/mus.24894
53. Lowes LP, Alfano LN, Crawfis R, et al. Reliability and validity of active-seated: An outcome in dystrophinopathy. *Muscle Nerve* 2015;52:356-362. doi:10.1002/mus.24557
54. Akima H, Lott D, Senesac C, et al. Relationships of thigh muscle contractile and non-contractile tissue with function, strength, and age in boys with Duchenne muscular dystrophy. *Neuromuscul Disord* 2012;22:16-25. doi:10.1016/j.nmd.2011.06.750
55. Azzabou N, Loureiro de Sousa P, Caldas E, Carlier PG. Validation of a generic approach to muscle water T2 determination at 3T in fat-infiltrated skeletal muscle. *J Magn Reson Imaging* 2015;41:645-653. doi:10.1002/jmri.24613
56. Barnard AM, Willcocks RJ, Finanger EL, et al. Skeletal muscle magnetic resonance biomarkers correlate with function and sentinel events in Duchenne muscular dystrophy. *PLoS One* 2018;13:e0194283. doi:10.1371/journal.pone.0194283
57. Bonati U, Hafner P, Schadelin S, et al. Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy. *Neuromuscul Disord* 2015;25:679-685. doi:10.1016/j.nmd.2015.05.006
58. Willcocks RJ, Rooney WD, Triplett WT, et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. *Ann Neurol* 2016;79:535-547. doi:10.1002/ana.24599
59. Strijkers GJ, Araujo ECA, Azzabou N, et al. Exploration of New Contrasts, Targets, and MR Imaging and Spectroscopy Techniques for Neuromuscular Disease - A Workshop Report of Working Group 3 of the Biomedicine and Molecular Biosciences COST Action BM1304 MYO-MRI. *Journal of Neuromuscular Diseases* 2019;6:1-30. doi:10.3233/Jnd-180333
60. Chou IJ, Tench CR, Gowland P, et al. Subjective discomfort in children receiving 3 T MRI and experienced adults' perspective on children's tolerability of 7 T: a cross-sectional questionnaire survey. *BMJ Open* 2014;4:e006094. doi:10.1136/bmjopen-2014-006094
61. Mercuri E, Pichiecchio A, Counsell S, et al. A short protocol for muscle MRI in children with muscular dystrophies. *Eur J Paediatr Neurol* 2002;6:305-307
62. Tornqvist E, Mansson A, Hallstrom I. Children having magnetic resonance imaging: A preparatory storybook and audio/visual media are preferable to anesthesia or deep sedation. *J Child Health Care* 2015;19:359-369. doi:10.1177/1367493513518374
63. Forbes SC, Walter GA, Rooney WD, et al. Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy. *Radiology* 2013;269:198-207. doi:10.1148/radiol.13121948
64. Wokke BH, Bos C, Reijnierse M, et al. Comparison of dixon and T1-weighted MR methods to assess the degree of fat infiltration in duchenne muscular dystrophy patients. *Journal of Magnetic Resonance Imaging* 2013;38:619-624. doi:10.1002/jmri.23998
65. Burakiewicz J, Sinclair CDJ, Fischer D, et al. Quantifying fat replacement of muscle by quantitative MRI in duchenne dystrophy. *Journal of neurology* 2017. doi:10.1007/s00415-017-8547-3
66. Hooijmans MT, Niks EH, Burakiewicz J, et al. Non-uniform muscle fat replacement along the proximodistal axis in Duchenne muscular dystrophy. *Neuromuscul Disord* 2017;27:458-464. doi:10.1016/j.nmd.2017.02.009
67. Ricotti V, Evans MR, Sinclair CD, et al. Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials. *PLoS One* 2016;11:e0162542. doi:10.1371/journal.pone.0162542
68. Hogrel JY, Wary C, Moraux A, et al. Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy. *Neurology* 2016;86:1022-1030. doi:10.1212/WNL.0000000000002464

69. Arpan I, Willcocks RJ, Forbes SC, et al. Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS. *Neurology* 2014;83:974-980. doi:10.1212/WNL.0000000000000775
70. Carlier PG. Global T2 versus water T2 in NMR imaging of fatty infiltrated muscles: different methodology, different information and different implications. *Neuromuscul Disord* 2014;24:390-392. doi:10.1016/j.nmd.2014.02.009
71. Keene KR, Beenakker JM, Hooijmans MT, et al. T2 relaxation-time mapping in healthy and diseased skeletal muscle using extended phase graph algorithms. *Magn Reson Med* 2020;84:2656-2670. doi:10.1002/mrm.28290
72. Dixon WT. Simple Proton Spectroscopic Imaging. *Radiology* 1984;153:189-194. doi:DOI 10.1148/radiology.153.1.6089263
73. Godi C, Ambrosi A, Nicastro F, et al. Longitudinal MRI quantification of muscle degeneration in Duchenne muscular dystrophy. *Ann Clin Transl Neurol* 2016;3:607-622. doi:10.1002/acn3.319
74. Wokke BH, van den Bergen JC, Versluis MJ, et al. Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy. *Neuromuscul Disord* 2014;24:409-416. doi:10.1016/j.nmd.2014.01.015
75. Forbes SC, Arora H, Willcocks RJ, et al. Upper and Lower Extremities in Duchenne Muscular Dystrophy Evaluated with Quantitative MRI and Proton MR Spectroscopy in a Multicenter Cohort. *Radiology* 2020;295:616-625. doi:10.1148/radiol.2020192210
76. Fischmann A, Hafner P, Gloor M, et al. Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. *Journal of neurology* 2013;260:969-974. doi:10.1007/s00415-012-6733-x
77. Wary C, Azzabou N, Giraudeau C, et al. Quantitative NMRI and NMRS identify augmented disease progression after loss of ambulation in forearms of boys with Duchenne muscular dystrophy. *NMR Biomed* 2015;28:1150-1162. doi:10.1002/nbm.3352
78. Willcocks RJ, Triplett WT, Forbes SC, et al. Magnetic resonance imaging of the proximal upper extremity musculature in boys with Duchenne muscular dystrophy. *Journal of neurology* 2017;264:64-71. doi:10.1007/s00415-016-8311-0
79. Gaeta M, Messina S, Mileto A, et al. Muscle fat-fraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessments. Preliminary experience. *Skeletal Radiol* 2012;41:955-961. doi:10.1007/s00256-011-1301-5

